Smith Matthew R, Bae Kyounghwa, Efstathiou Jason A, Hanks Gerald E, Pilepich Miljenko V, Sandler Howard M, Shipley William U
Department of Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
J Clin Oncol. 2008 Sep 10;26(26):4333-9. doi: 10.1200/JCO.2008.16.5845.
Diabetes is associated with lower risk of prostate cancer. Most men with diabetes are obese, and obesity is associated with greater prostate cancer mortality. Whether diabetes influences outcomes after prostate cancer diagnosis is unknown.
We assessed the relationship between prevalent diabetes and mortality using data from Radiation Therapy Oncology Group Protocol 92-02, a large randomized trial of men (N = 1,554) treated with radiation therapy and short-term versus long-term adjuvant goserelin for locally advanced prostate cancer. Regression and proportional hazard models were performed to evaluate relationships between prevalent diabetes and all-cause mortality, prostate cancer mortality, and non-prostate cancer mortality. Covariates included age, race, tumor stage, Gleason score, prostate-specific antigen, weight, and treatment arm.
There were a total of 765 deaths; 210 (27%) were attributed to prostate cancer. In univariate analyses, prevalent diabetes was associated with greater all-cause mortality and non-prostate cancer mortality but not prostate cancer mortality. After controlling for other covariates, prevalent diabetes remained significantly associated with greater all-cause mortality and non-prostate cancer mortality (hazard ratio [HR] = 2.12; 95% CI, 1.69 to 2.66; P < .0001) but not prostate cancer mortality (HR = 0.80; 95% CI, 0.51 to 1.25; P = .34). In contrast, weight was associated with greater prostate cancer mortality (HR = 1.77; 95% CI, 1.22 to 2.55; P = .002) but not all-cause or non-prostate cancer mortality.
Weight but not prevalent diabetes is associated with greater prostate cancer mortality in men receiving combined modality treatment for locally advanced disease. These observations suggest that the association between obesity and greater prostate cancer mortality is mediated by mechanism(s) other than the characteristic metabolic alterations of diabetes.
糖尿病与前列腺癌风险较低相关。大多数糖尿病男性肥胖,而肥胖与更高的前列腺癌死亡率相关。糖尿病是否会影响前列腺癌诊断后的预后尚不清楚。
我们使用放射治疗肿瘤学组92 - 02方案的数据评估了糖尿病与死亡率之间的关系,该方案是一项针对1554名男性的大型随机试验,这些男性因局部晚期前列腺癌接受放射治疗,并接受短期与长期辅助戈舍瑞林治疗。采用回归模型和比例风险模型评估糖尿病与全因死亡率、前列腺癌死亡率及非前列腺癌死亡率之间的关系。协变量包括年龄、种族、肿瘤分期、 Gleason评分、前列腺特异性抗原、体重及治疗组。
共有765例死亡;210例(27%)归因于前列腺癌。在单因素分析中,糖尿病与更高的全因死亡率和非前列腺癌死亡率相关,但与前列腺癌死亡率无关。在控制其他协变量后,糖尿病仍与更高的全因死亡率和非前列腺癌死亡率显著相关(风险比[HR]=2.12;95%可信区间,1.69至2.66;P<.0001),但与前列腺癌死亡率无关(HR = 0.80;95%可信区间,0.51至1.25;P = 0.34)。相比之下,体重与更高的前列腺癌死亡率相关(HR = 1.77;95%可信区间,1.22至2.55;P = 0.002),但与全因死亡率或非前列腺癌死亡率无关。
在接受局部晚期疾病综合治疗的男性中,体重而非糖尿病与更高的前列腺癌死亡率相关。这些观察结果表明,肥胖与更高的前列腺癌死亡率之间的关联是由糖尿病特征性代谢改变以外的机制介导的。